- Colgate-Palmolive Co (NYSE:CL) reported fourth-quarter FY22 sales growth of 5% year-on-year to $4.629 billion, beating the consensus of $4.59 billion.
- Organic sales increased by 8.5%. Total Oral, Personal, and Home Care net sales increased by 1.4% to $3.6 billion.
- Non-GAAP EPS of $0.77 beat the analyst consensus of $0.76.
- During Q4, the company took a non-cash, after-tax charge of $620 million to adjust the carrying values of goodwill and intangible assets related to the Filorga skin health business.
- Gross profit was $2.57 billion, while the margin contracted 250 basis points to 55.6%.
- Selling, general and administrative expenses rose 2.1% to $1.6 billion.
- Operating margin contracted 390 basis points to 4.4%, and operating income for the quarter fell 44.6% to $202 million.
- The company held $775 million in cash and equivalents as of Dec. 31, 2022. Net cash provided by operations was $2.55 billion for 2022.
- “We are also strengthening and scaling our digital, data analytics, innovation and other capabilities across the company,” said Chairman, President, and CEO Noel Wallace.
- Outlook: Colgate sees FY23 organic sales growth of 2% – 5%.
- The company expects organic sales growth to be towards the high end of its long-term targeted range of 3% to 5%.
- On a non-GAAP basis, the company expects gross profit margin expansion, increased advertising investment, and low to mid-single-digit EPS growth.
- Price Action: CL shares are trading lower by 3.22% at $73.10 in premarket on the last check Friday.
Morgan Analyst Analyst Expects AI Growth To Weigh Heavier On Power Grid Than EVs
Morgan Stanley also forecasts 90 megatons of annual carbon dioxide emission from U.S. data centers by 2027, equivalent to emissions of about 14 million gas cars.
